This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Prudent Investors Are Snapping Up Ensign (ENSG) Stock Now
by Zacks Equity Research
Ensign (ENSG) expects to witness strong acquisition opportunities in the fall of this year.
Here's Why Encompass Health (EHC) Stock is a Strong Buy Now
by Zacks Equity Research
Encompass Health's (EHC) focus on boosting the number of licensed beds and hospitals will likely enhance market density and build scale.
Brookdale Senior (BKD) Shares Jump 18.7% Since Q2 Earnings Beat
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $73-$78 million range in the third quarter.
The Joint (JYNT) Reaches 900th Clinic Mark With New Texas Unit
by Zacks Equity Research
The Joint (JYNT) moves from the 800th to the 900th clinic milestone in less than a year.
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.
Will US Business Strength Aid Acadia's (ACHC) Q2 Earnings?
by Zacks Equity Research
Strength in US operations, stemming from higher patient days and revenue per patient day, is expected to have aided Acadia Healthcare's (ACHC) Q2 performance. Rising expenses are likely to have partially offset the same.
Best Value Stocks to Buy for July 25th
by Zacks Equity Research
MOV, SEM and JACK made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 25, 2023.
Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y
by Zacks Equity Research
Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.
Select Medical (SEM) Up 21% Year to Date: More Room to Run?
by Zacks Equity Research
Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.
Company News for Jul 5, 2023
by Zacks Equity Research
Companies in The News Are: WFC, SEM, RIVN, TSLA, MRVL
The Joint Corp. (JYNT) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
by Zacks Equity Research
Select Medical (SEM) expects revenues to be within the range of $6.5-$6.7 billion in 2023, indicating a rise of 4.8% from the 2022 figure of $6.3 billion.
Select Medical (SEM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 51.35% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Q1 Earnings Beat Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 13.26% and 1.04%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Misses Q1 Earnings Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -5.38% and 7.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Buys Richmond Post-Acute Care Facility
by Zacks Equity Research
Select Medical (SEM) acquires the Vibra Hospital of Richmond to provide enhanced critical illness recovery care across Virginia.
Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care
by Zacks Equity Research
Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.
Select Medical (SEM) Forays Into Indiana With Lutheran Health JV
by Zacks Equity Research
Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.
Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.
Select Medical (SEM) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -33.33% and 2.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect improved figures in the Rehabilitation Hospital business.
Select Medical (SEM) Enters JV to Boost New Jersey Healthcare
by Zacks Equity Research
Select Medical (SEM) collaborates with AtlantiCare to open an inpatient rehabilitation hospital and jointly manage the operations of SEM's outpatient centers across New Jersey.
Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings Miss
by Zacks Equity Research
Select Medical (SEM) reports improved performance in the Rehabilitation Hospital unit for the third quarter.
Select Medical (SEM) Q3 Earnings Miss Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?